Here is a breakdown of major shareholders in Chembio Diagnostics Inc. (NASDAQ: CEMI)

Chembio Diagnostics Inc. (NASDAQ: CEMI) is -17.21% lower on its value in year-to-date trading and has touched a low of $2.25 and a high of $15.89 in the current 52-week trading range. The CEMI stock was last observed hovering at around $4.59 in the last trading session, with the day’s loss setting it -0.81% off its average median price target of $5.00 for the next 12 months. It is also 24.4% off the consensus price target high of $5.00 offered by 4 analysts, but current levels are 24.4% higher than the price target low of $5.00 for the same period.

Currently trading at $3.78, the stock is -29.38% and -20.13% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.38 million and changing -17.76% at the moment leaves the stock -37.30% off its SMA200. CEMI registered -23.89% loss for a year compared to 6-month gain of -15.17%. The firm has a 50-day simple moving average (SMA 50) of $5.1686 and a 200-day simple moving average (SMA200) of $6.7587.

The stock witnessed a -25.40% loss in the last 1 month and extending the period to 3 months gives it a -60.80%, and is -27.68% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.37% over the week and 9.11% over the month.

Chembio Diagnostics Inc. (CEMI) has around 295 employees, a market worth around $78.33M and $28.50M in sales. Profit margin for the company is -71.90%. Distance from 52-week low is 67.78% and -76.24% from its 52-week high. The company has generated returns on investments over the last 12 months (-30.50%).

Chembio Diagnostics Inc. (CEMI) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Chembio Diagnostics Inc. (CEMI) is a “Hold”. 4 analysts offering their recommendations for the stock have an average rating of 3.00, where 4 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Chembio Diagnostics Inc. is expected to release its quarterly report on 11/05/2020 and quarterly earnings per share for the current quarter are estimated at -$0.28 with sales reaching $4.25M over the same period. The EPS is expected to shrink by -48.00% this year, but quarterly earnings will post -37.10% year-over-year. Quarterly sales are estimated to shrink -56.30% in year-over-year returns.

Chembio Diagnostics Inc. (CEMI) Top Institutional Holders

50 institutions hold shares in Chembio Diagnostics Inc. (CEMI), with 3.85M shares held by insiders accounting for 19.10% while institutional investors hold 51.97% of the company’s shares. The shares outstanding are 18.87M, and float is at 17.30M with Short Float at 30.98%. Institutions hold 42.04% of the Float.

Chembio Diagnostics Inc. (CEMI) Insider Activity

A total of 1 insider transactions have happened at Chembio Diagnostics Inc. (CEMI) in the last six months, with sales accounting for 1 and purchases happening 0 times. The most recent transaction is an insider purchase by Potthoff John Gary, the company’s Director. SEC filings show that Potthoff John Gary bought 10,000 shares of the company’s common stock on Nov 11 at a price of $4.44 per share for a total of $44400.0. Following the purchase, the insider now owns 37772.0 shares.

Chembio Diagnostics Inc. (CEMI): Who are the competitors?

The company’s main competitors (and peers) include OraSure Technologies Inc. (OSUR) that is 70.81% higher over the past 12 months. Bio-Rad Laboratories Inc. (BIO) is 48.35% up on the 1-year trading charts. Short interest in the company’s stock has risen 23.77% from the last report on Jul 14, 2020 to stand at a total of 4.04 million short shares sold with a short interest ratio of 0.75.